- No file added yet -

Supplementary Data from Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

dataset

posted on 2023-03-31, 05:21 authored by Russell Moser, James Annis, Olga Nikolova, Cliff Whatcott, Kay Gurley, Eduardo Mendez, Kim Moran-Jones, Craig Dorrell, Rosalie C. Sears, Calvin Kuo, Haiyong Han, Andrew Biankin, Carla Grandori, Daniel D. Von Hoff, Christopher J. Kemp

Funding

Canary Foundation, Listwin Foundation, and Gregory Fund

Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research

History

ARTICLE ABSTRACT

This study utilizes functional genetic and pharmacological profiling of KRAS-mutant pancreatic adenocarcinoma to identify therapeutic strategies and finds that TFIIH inhibition synergizes with TRAIL to induce apoptosis in KRAS-driven pancreatic cancer.